Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CONFIRM: Fulvestrant 500 mg vs 250 mg in Advanced Breast Cancer
NCT00099437Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Feb 2005
- Primary completion
- Feb 2009
- Modality
- Small Molecules
- Countries
- 17
01
Overview
A Phase 3 trial of fulvestrant in breast cancer, sponsored by AstraZeneca. Started Feb 2005; status: active, not recruiting.
02
Drugs
fulvestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00099437.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00099437.